Qianglan Lu

Sep 16, 2024 | onlinelibrary.wiley.com | Qianglan Lu |Ruiyue Chen |Fei Zeng |zhiyong Liu

Conflict of Interest The authors declare no conflict of interest. Supporting Information Filename Description adfm202408767-sup-0001-SuppMat.docx9 MB Supporting Information References 1a) , , , , , , Transl Lung Cancer Res 2023, 12, 2129; b) , , , , , , , , , , , , , , , , , , , , , , , , , , , J Thorac Oncol 2021, 16, 1136; c) , , , , Ca-Cancer J. Clin. 2023, 73, 17.

Feb 22, 2024 | pericles.pericles-prod.literatumonline.com | Fei Zeng |Yongchun Pan |Qianglan Lu |Xiaowei Luan

Employing tumor whole cells for tumor immunotherapy is a promising tumor therapy proposed in the early stage, but its therapeutic efficacy is weakened by the methods of eliminating pathogenicity and the mass ratio of the effective antigen carried by itself.